Pharma Mar, S.A. (BME:PHM)

Pharma Mar Statistics

Total Valuation

Pharma Mar has a market cap or net worth of EUR 1.44 billion. The enterprise value is 1.35 billion.

Market Cap	1.44B
Enterprise Value	1.35B

Important Dates

The next estimated earnings date is Friday, July 25, 2025.

Earnings Date	Jul 25, 2025
Ex-Dividend Date	Jun 25, 2025

Share Statistics

Pharma Mar has 17.57 million shares outstanding.

Current Share Class	17.57M
Shares Outstanding	17.57M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	11.79%
Owned by Institutions (%)	9.56%
Float	12.74M

Valuation Ratios

The trailing PE ratio is 72.46 and the forward PE ratio is 28.80. Pharma Mar's PEG ratio is 0.11.

PE Ratio	72.46
Forward PE	28.80
PS Ratio	8.20
PB Ratio	7.29
P/TBV Ratio	7.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	0.11

Enterprise Valuation

The stock's EV/EBITDA ratio is 97.59, with an EV/FCF ratio of -75.95.

EV / Earnings	67.99
EV / Sales	7.69
EV / EBITDA	97.59
EV / EBIT	175.91
EV / FCF	-75.95

Financial Position

The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.26.

Current Ratio	2.97
Quick Ratio	2.23
Debt / Equity	0.26
Debt / EBITDA	3.75
Debt / FCF	-2.92
Interest Coverage	2.34

Financial Efficiency

Return on equity (ROE) is 10.19% and return on invested capital (ROIC) is 1.99%.

Return on Equity (ROE)	10.19%
Return on Assets (ROA)	1.44%
Return on Invested Capital (ROIC)	1.99%
Return on Capital Employed (ROCE)	3.02%
Revenue Per Employee	351,494
Profits Per Employee	39,752
Employee Count	500
Asset Turnover	0.53
Inventory Turnover	0.21

Taxes

Income Tax	-9.03M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +113.19% in the last 52 weeks. The beta is -0.11, so Pharma Mar's price volatility has been lower than the market average.

Beta (5Y)	-0.11
52-Week Price Change	+113.19%
50-Day Moving Average	82.47
200-Day Moving Average	80.25
Relative Strength Index (RSI)	51.11
Average Volume (20 Days)	39,157

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharma Mar had revenue of EUR 175.75 million and earned 19.88 million in profits.

Revenue	175.75M
Gross Profit	165.93M
Operating Income	7.68M
Pretax Income	10.85M
Net Income	19.88M
EBITDA	11.73M
EBIT	7.68M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 140.85 million in cash and 51.94 million in debt, giving a net cash position of 88.91 million or 5.06 per share.

Cash & Cash Equivalents	140.85M
Total Debt	51.94M
Net Cash	88.91M
Net Cash Per Share	5.06
Equity (Book Value)	197.47M
Book Value Per Share	n/a
Working Capital	156.52M

Cash Flow

In the last 12 months, operating cash flow was -9.56 million and capital expenditures -8.23 million, giving a free cash flow of -17.79 million.

Operating Cash Flow	-9.56M
Capital Expenditures	-8.23M
Free Cash Flow	-17.79M
FCF Per Share	-1.01

Margins

Gross margin is 94.41%, with operating and profit margins of 4.37% and 11.31%.

Gross Margin	94.41%
Operating Margin	4.37%
Pretax Margin	6.17%
Profit Margin	11.31%
EBITDA Margin	6.67%
EBIT Margin	4.37%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 1.00%.

Dividend Per Share	0.80
Dividend Yield	1.00%
Dividend Growth (YoY)	23.08%
Years of Dividend Growth	1
Payout Ratio	57.46%
Buyback Yield	n/a
Shareholder Yield	1.00%
Earnings Yield	1.38%
FCF Yield	-1.24%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.

Last Split Date	Jul 22, 2020
Split Type	Reverse
Split Ratio	0.0833333333

Scores

Pharma Mar has an Altman Z-Score of 6.33 and a Piotroski F-Score of 5.

Altman Z-Score	6.33
Piotroski F-Score	5